Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Fluphenazine Hydrochloride Tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths.
The fluphenazine hydrochloride tablet market had U.S. sales of approximately $30 million for the 12 months ending January 2023 according to IQVIA. Fluphenazine Hydrochloride Tablets are a generic version of the brand product, Prolixin®.*
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings brands and generics to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
For more information, visit www.upsher-smith.com.